Key facts
- This page summarizes Amit Kumar's Form 4 filing for Anixa Biosciences Inc (ANIX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 06 Jan 2026, 19:42.
Amit Kumar - 05 Jan 2026 Form 4 Insider Report for Anixa Biosciences Inc (ANIX)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- ANIX
- Reported as of
- 05 Jan 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Jan 2026, 19:42:43 UTC
- Prior SEC filing
- 31 Oct 2025
- Next SEC filing
- 16 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Amit Kumar
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Amit Kumar filed Form 4 for Anixa Biosciences Inc (ANIX) on 06 Jan 2026.
Change
- Previous filing in this sequence was filed on 31 Oct 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001191905
Primary reporting owner
KUMAR AMIT
- Relationship
- Chief Executive Officer, Director
- Address
- C/O ANIXA BIOSCIENCES, INC., 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE,
- Signature
- /s/ Amit Kumar
- Signature date
- 06 Jan 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ANIX
transaction
Derivative
Employee Stock Option
Award
- Transaction value
- $0
- Shares
- +350,000
- Change %
- Price
- $0.000000
- Shares after
- 350,000
- Date
- 05 Jan 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 350,000
- Exercise price
- $3.18
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan.
Footnote F2
The options vest and become exercisable in thirty-six (36) equal monthly installments beginning January 31, 2026.